SHANGHAI, July 6 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Sundia has acquired Protein Folding Shape Code (PFSC) technology for doing probe binding site for drug discovery from Microtech Nano LLC, a R&D Company in Indianapolis, IN, USA. As a part of this business deal, Dr. Jiaan Yang, the founder and President of Microtech Nano LLC joins Sundia as Vice President of Drug Discovery Technology.
Dr. Yang was trained as a physical chemist. In his 26 year professional career in pharmaceutical, biotech and nanotechnology industries in USA, he accumulated a broad range of experience in bioinformatics with expertise in theoretical chemistry, quantum chemistry, computational chemistry, molecular biology and computer information technology.
In recent years, Dr. Yang quit his job from Eli Lilly and devoted 3 years to research and to develop an innovative method to describe protein complex 3D structure, and achieved PFSC, an outstanding success. For a long time, it has been a great challenge to protein chemists and biologists how to obtain a complete description of protein 3D structure, including the irregular shapes of loops and coils. With his expertise in multiple fields, Dr. Yang applied mathematics on this biology subject, generated a set of Protein Folding Shape Code (PFSC) for a complete description of protein's complex 3D structure, and developed computer software to process protein data. The success of PFSC is a big scientific breakthrough in structural biology research.
Sundia's Chairman and CEO Dr. Xiaochuan Wang commented that "the application of PFSC technology will bring a great impact to pharmaceutical research and drug discovery." According to her, the PFSC is able to effectively screen protein 3D structure database, probe new indications, explore potential side effects, and help better understanding drug and disease mechanisms on a molecular level and quantitative assessment for ligand-binding site to assist drug design.
"With PFSC, Sundia can serve our client companies new drug discovery needs more effectively. Scientists like Dr. Yang, who has a solid scientific skill set, as well as a strong business mindset and entrepreneurial spirit will greatly enhance our CRO service level," said Dr. Xiaochuan Wang.
Dr. Yang holds a Ph.D. degree in physical chemistry from Louisiana State University in USA, supervised by Dr. Neil Kestner. He also received a M.S. degree from Theoretical Chemistry Institute, Jilin University in China, with Professor Tang Aoqing.
About Sundia: Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) company based in Shanghai, China, to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, formulation development, API manufacture, and regulatory submission. For more information, please visit http://www.sundia.com .